GIKLY
Grifols SA
$5.69
0.00%
No data for this timeframe.
Vol
SEC Reports3
Recent Activity
May 15, 2026
SEC
Grifols filed a 6-K on May 15, 2026, calling an Ordinary General Shareholders' Meeting for June 17-18, 2026. The agenda
6-K — Impact 3/10
May 7, 2026
SEC
Grifols reported Q1 2026 revenue of €1.7 billion (+3.3% cc, -4.8% reported), net profit up 21.9% to €73 million, and adj
6-K — Impact 5/10
Apr 17, 2026
SEC
Grifols completed a major debt refinancing in April 2026, securing $4.265 billion in new term loans and a revolving cred
20-F — Impact 6/10
Analyst Ratings
5Strong Buy
9Buy
5Hold
2Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 2 mixed, 1 neutral. Avg impact: 4.7/10.
NEUTRAL
6-K
3/10
Grifols filed a 6-K on May 15, 2026, calling an Ordinary General Shareholders' Meeting for June 17-1
May 15, 2026
MIXED
6-K
5/10
Grifols reported Q1 2026 revenue of €1.7 billion (+3.3% cc, -4.8% reported), net profit up 21.9% to
May 7, 2026
MIXED
20-F
6/10
Grifols completed a major debt refinancing in April 2026, securing $4.265 billion in new term loans
Apr 17, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 67% buy across 21 analysts — 5 strong buy, 9 buy, 5 hold, 2 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $2.0B | 3.2% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $2.0B | 5.7% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $7.7B | 2.1% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $8.2B | 6.5% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| May 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| Apr 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| Mar 1, 2026 | 5 | 10 | 4 | 2 | 0 | 71% | |
| Feb 1, 2026 | 5 | 10 | 4 | 2 | 0 | 71% | |
| Jan 1, 2026 | 3 | 11 | 4 | 2 | 0 | 70% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 1, 2026
Clinical Trial
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Phase Phase 2 — COMPLETED